Mammary ONcology Assessment of LEE011’s Efficacy and SAfety
Ribociclib (LEE011) Investigational Study for Breast Cancer
Are you interested in joining a clinical study for women and men with HR+/HER2- breast cancer?
Novartis is now recruiting patients who have breast cancer that is hormone receptor positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-).
By participating in this breast cancer trial, you may receive an investigational drug in combination with another drug that is commonly used to treat HR+/HER2- breast cancer. All study participants will receive care from a study team of health care professionals at a clinical trial site.
Breast cancer cells grow and divide uncontrollably. This uncontrolled growth can be caused by certain proteins called cyclin-dependent kinases, which can be overactivated in some breast cancer cells. An investigational drug has been developed by researchers that targets and blocks cyclin-dependent kinases. Drugs that block cyclin-dependent kinases may be able to slow or stop cancer growth.
As with all clinical trials, you have the right to leave the study at any time, for any reason.